# A Study of BGM0504 in Participants With Type 2 Diabetes

Study · id `cardio:ct-nct06716216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06716216](<https://clinicaltrials.gov/study/NCT06716216>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06716216

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 553 participants.

## Technical summary

Registry record NCT06716216. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2026-08-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 553 participants (enrolled count; ClinicalTrials.gov record NCT06716216, source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)
- Started: 2025-01-13 (actual) (ClinicalTrials.gov record NCT06716216, source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2026-08-25 (actual) (ClinicalTrials.gov record NCT06716216, source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)
- Completion: 2026-08-25 (actual) (ClinicalTrials.gov record NCT06716216, source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06716216, source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06716216-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of BGM0504 in Participants With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Drug: 5 mg BGM0504 Administered SC
- Intervention (Drug): Drug:10 mg BGM0504 Administered SC
- Intervention (Drug): Drug: Semaglutide Administered SC
- Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: BrightGene Bio-Medical Technology Co., Ltd. (`cardio:org-brightgene-bio-medical-technology-co-ltd`)

## Provenance

Content hash: a7678ea5e1562fe7a0f1d4964734dd5144b6a3e045fac3bcdd8aecaa2f2b4720
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
